New treatment for women with angina and nonobstructive coronary artery disease.
Official title: Innovative Therapy to Treat Women with Angina with Nonobstructive CAD (ANOCA) and Coronary Microvascular Disease
Funded at University of Virginia · NIH-10951264 · Data updated 2026-11-12
This study is looking at a new treatment for women who have angina due to nonobstructive coronary artery disease and coronary microvascular disease, using a diabetes medication to help improve heart function and ease their symptoms.
Quick facts
| Grant type | Career grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Virginia NIH-funded |
| Lab location | 1 site (Charlottesville, United States) |
| Project start | September 1, 2024 |
| Project end | August 31, 2029 |
| Funding year | 2024 |
| Award (this year) | $162,000 |
| NIH project number | 1K01HL174889-01 |
| Project ID | NIH-10951264 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are women experiencing angina with nonobstructive coronary artery disease or coronary microvascular disease.
✕Less likely to help
Patients with obstructive coronary artery disease or those not experiencing angina may not benefit from this research.
What this research studies
This research focuses on developing an innovative therapy specifically for women suffering from angina related to nonobstructive coronary artery disease (ANOCA) and coronary microvascular disease (CMD). It recognizes that heart disease manifests differently in women compared to men, particularly in the context of microvascular dysfunction. The study will explore the use of sodium-glucose cotransporter 2 inhibitors (SGLT2i), a class of drugs typically used for diabetes, to improve heart function and reduce symptoms in these patients. By tailoring treatment to the unique needs of women, the research aims to enhance understanding and management of heart disease in this population.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for women with angina, improving their quality of life and reducing heart disease-related complications.
How similar studies have gone: Previous studies have shown promising results using SGLT2 inhibitors in improving heart function, indicating potential success for this novel approach.
Where this research is happening
-
University of Virginia
Charlottesville, United States Active
Researchers
- Principal investigator: Rodriguez Lozano, Patricia Fiorella — University of Virginia
- Study coordinator: Rodriguez Lozano, Patricia Fiorella
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.